Humanigen Announces COVID-19 Case Report Demonstrating Rapid Resolution and Discharge after Single IND Emergency Use ...
(WorldNews Business)

BURLINGAME, Calif.--(BUSINESS WIRE)--Oct 2, 2020-- Humanigen, Inc., (Nasdaq: HGEN) (“Humanigen”), a clinical stage biopharmaceutical company focused on preventing and treating an immune hyper-response called ‘cytokine storm,` today announced that a patient case report on the use of lenzilumab™ in critical COVID-19 was published online at OSF Preprints. The case report, titled “COVID-19 associated chronic ARDS successfully treated with lenzilumab” is available at: https://osf.io/xusr9/. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201002005105/en/ The published case describes a 77-year-old Caucasian male patient with a past...